Warm Antibody Hemolytic Anemia (WAIHA) is an autoimmune disorder characterized by the premature destruction of healthy red blood cells by autoantibodies. It is a common disorder directed against self RBCs.
Warm Autoimmune Hemolytic Anemia market size in 7MM in 2017wasUSD 368 million
Warm Autoimmune Hemolytic Anemia current market does not possess any approved therapy and relies only on the symptomatic treatment alternatives. The management of WAIHA has long been and still is mainly empirical or based on uncontrolled retrospective studies. The treatment landscape is primarily occupied by transfusion and supportive measures, corticosteroids, intravenous immunoglobulin (IVIG), danazol, rituximab, splenectomy, immunosuppressive drugs, and lastly hematopoietic stem cell transplantation (HSCT).
In a nutshell, it can be summarized that the traditional treatment options for WAIHA include corticosteroids, splenectomy, and conventional immunosuppressive drugs. Over the years, however, newer options have become available with considerable evidence of success.
They are used mainly in patients who fail to respond to splenectomy, those who relapse after splenectomy, and those who cannot maintain stable hemoglobin levels without unacceptably high doses of corticosteroids. Considering the high unmet medical need and the shortage of approved products, research is ongoing to develop other novel therapies. Although it is too soon to predict their market presence, it can be assumed that the landscape composition will undergo a significant transition in the near future.
The dynamics of the WAIHA market are anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies, i.e., Fostamitinib (Rigel Therapeutics), APL-2 (Apellis Pharmaceuticals), M281 (Momenta Pharmaceuticals), and few others during the forecast period 2020–2030.
Warm Autoimmune Hemolytic Anemia Market Drivers
- Increased market opportunity
- Increasing awareness
- Increase in number of research initiatives
Warm Autoimmune Hemolytic Anemia Market Barriers
- Diagnostic delays in case of idiopathic WAIHA
- Lack of approved therapies
- Chances of relapse
Request for sample pages
Table of contents
1. Key Insights
2. Executive Summary
3. SWOT Analysis
4. wAIHA Market Overview at a Glance
4.1. Market Share (%) Distribution of wAIHA in 2017
4.2. Market Share (%) Distribution of wAIHA in 2030
5. Disease Background and Overview
5.1. Introduction
5.2. Types
5.3. Causes
5.4. Signs and Symptoms
5.5. Pathophysiology
5.6. Manifestations
5.7. Diagnosis
- Immunohematological assessment of patients with AIHA
- DAT-negative AIHA
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. KOL Views
6.3. 7MM Total Prevalent Patient Population of wAIHA
6.4. Assumptions and Rationale: 7MM
7. Country Wise-Epidemiology of wAIHA
7.1. The United States
7.1.1. Total Prevalent Cases of AIHA in the United States
7.1.2. Diagnosed Prevalence of wAIHA in the United States
7.1.3. Type-specific Prevalence of wAIHA in the United States
7.1.4. Gender-specific Prevalence of wAIHA in the United States
7.2. EU5
7.2.1. Germany
7.2.1.1. Total Prevalent Cases of AIHA in Germany
7.2.1.2. Diagnosed Prevalence of wAIHA in Germany
7.2.1.3. Type-specific Prevalence of wAIHA in Germany
7.2.1.4. Gender-specific Prevalence of wAIHA in Germany
7.2.2. France
7.2.2.1. Total Prevalent Cases of AIHA in France
7.2.2.2. Diagnosed Prevalence of wAIHA in France
7.2.2.3. Type-specific Prevalence of wAIHA in France
7.2.2.4. Gender-specific Prevalence of wAIHA in France
7.2.3. Italy
7.2.3.1. Total Prevalent Cases of AIHA in Italy
7.2.3.2. Diagnosed Prevalence of wAIHA in Italy
7.2.3.3. Type-specific Prevalence of wAIHA in Italy
7.2.3.4. Gender-specific Prevalence of wAIHA in Italy
7.2.4. Spain
7.2.4.1. Total Prevalent Cases of AIHA in Spain
7.2.4.2. Diagnosed Prevalence of wAIHA in Spain
7.2.4.3. Type-specific Prevalence of wAIHA in Spain
7.2.4.4. Gender-specific Prevalence of wAIHA in Spain
7.2.5. The United Kingdom
7.2.5.1. Total Prevalent Cases of AIHA in the UK
7.2.5.2. Diagnosed Prevalence of wAIHA in the UK
7.2.5.3. Type-specific Prevalence of wAIHA in the UK
7.2.5.4. Gender-specific Prevalence of wAIHA in the UK
7.3. Japan
7.3.1. Total Prevalent Cases of AIHA in Japan
7.3.2. Diagnosed Prevalence of wAIHA in Japan
7.3.3. Type-specific Prevalence of wAIHA in Japan
7.3.4. Gender-specific Prevalence of wAIHA in Japan
8. Treatment and Management of wAIHA
8.1. Sequential approach to treatment options for w-AIHA and common dosing regimens
8.1.1. First-line therapy
8.1.1.1. Corticosteroids
8.1.2. Second-line therapy
8.1.2.1. Splenectomy
8.1.2.2. Rituximab
8.1.2.3. Immunosuppressive drugs
8.1.2.4. Other Options
8.2. British Guidelines for WAIHA treatment
9. Case Study
10. Patient Journey
12. Unmet Needs
13. Emerging Therapies
13.1. Fostamatinib: Rigel Pharmaceuticals
13.1.1. Product Description
13.1.2. Other Development Activities
13.1.3. Clinical Development
13.1.3.1. Clinical Trials Information
13.1.4. Safety and Efficacy
13.2. APL-2: Apellis Pharmaceuticals, Inc.
13.2.1. Product Description
13.2.2. Other Development Activities
13.2.3. Clinical Development
13.2.3.1. Clinical Trials Information
13.2.4. Safety and Efficacy
13.3. M281: Momenta Pharmaceuticals
13.3.1. Product Description
13.3.2. Other Development Activities
13.3.3. Clinical Development
13.3.3.1. Clinical Trials Information
13.3.4. Safety and Efficacy
13.4. IMVT-1401: Immunovant
13.4.1. Product Description
13.4.2. Other Development Activities
13.4.3. Clinical Development
13.4.3.1. Clinical Trials Information
13.4.4. Safety and Efficacy
13.5. ALXN1830/SYNT001: Alexion Pharmaceuticals, Inc.
13.5.1. Product Description
13.5.2. Other Development Activities
13.5.3. Clinical Development
13.5.4. Clinical Trials Information
13.5.5. Product Profile
14. Other Promising Candidates
14.1. BIV009 (Sutimlimab): Sanofi
14.1.1. Product Description
14.1.2. Other Development Activities
14.1.3. Clinical Development
14.1.4. Clinical Trials Information
14.1.5. Safety and Efficacy
14.1.6. Product Profile
15. wAIHA: 7 Major Market Analysis
15.1. Key Findings
15.2. Market Size of wAIHA in 7MM
15.3. KOL Views
16. Market Outlook by Country
16.1. The United States: Market Outlook
16.2. United States Market Size
16.2.1. Total Market Size of wAIHA
16.2.2. Market Size of wAIHA by Therapies
17. EU-5 Countries: Market Outlook
17.1. Germany
17.1.1. Total Market size of wAIHA
17.1.2. Market Size of wAIHA by Therapies
17.2. France
17.2.1. Total Market Size of wAIHA
17.2.2. Market Size of wAIHA by Therapies
17.3. Italy
17.3.1. Total Market Size of wAIHA
17.3.2. Market Size of wAIHA by Emerging Therapies
17.4. Spain
17.4.1. Total Market Size of wAIHA
17.4.2. Market Size of wAIHA by Therapies
17.5. United Kingdom
17.5.1. Total Market Size of wAIHA
17.5.2. Market Size of wAIHA by Therapies
18. Japan: Market Outlook
18.1.1. Total Market Size of wAIHA
18.1.2. Market Size of wAIHA by Therapies
19. Market Drivers
20. Market Barriers
21. Appendix
21.1. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/